Characterizing treatment interruptions in the OPERA cohort and virologic outcomes after resumption with bictegravir/emtricitabine/tenofovir alafenamide.
- DOI
- 10.1186/s12981-025-00769-x
- Published
- 2025 Jul 21
- Container
- AIDS research and therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s12981-025-00769-x,
title = {Characterizing treatment interruptions in the OPERA cohort and virologic outcomes after resumption with bictegravir/emtricitabine/tenofovir alafenamide.},
author = {Mounzer K and Osterman MD and Brunet L and Hsu RK and Pierone G Jr and Fusco JS and Prata Menezes N and Gruber J and Lim T and Dunbar M and Fusco GP},
year = {2025},
journal = {AIDS research and therapy},
doi = {10.1186/s12981-025-00769-x},
url = {https://doi.org/10.1186/s12981-025-00769-x}
}RIS
TY - JOUR TI - Characterizing treatment interruptions in the OPERA cohort and virologic outcomes after resumption with bictegravir/emtricitabine/tenofovir alafenamide. AU - Mounzer K AU - Osterman MD AU - Brunet L AU - Hsu RK AU - Pierone G Jr AU - Fusco JS AU - Prata Menezes N AU - Gruber J AU - Lim T AU - Dunbar M AU - Fusco GP PY - 2025 JO - AIDS research and therapy DO - 10.1186/s12981-025-00769-x UR - https://doi.org/10.1186/s12981-025-00769-x ER -
APA
K, M., MD, O., L, B., RK, H., Jr, P. G., JS, F., N, P. M., J, G., T, L., M, D., & GP, F. (2025). Characterizing treatment interruptions in the OPERA cohort and virologic outcomes after resumption with bictegravir/emtricitabine/tenofovir alafenamide.. AIDS research and therapy. https://doi.org/10.1186/s12981-025-00769-x
Source records
- pubmed · retrieved 2026-09-26T09:45:49.104Z